1. Signaling Pathways
  2. Membrane Transporter/Ion Channel
  3. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-14834A
    Budiodarone tartrate
    Inhibitor 98.14%
    Budiodarone (ATI-2042) tartrate is a chemical analogue of Amiodarone (HY-14187) with balanced, multiple cardiac ion channel (potassium, sodium and calcium channels) inhibiting activity. Budiodarone tartrate is an antiarrhythmic agent.
    Budiodarone tartrate
  • HY-101362
    QX-222 chloride
    Inhibitor
    QX-222 chloride, a trimethyl analogue of Lignocaine (HY-B0185), is a potent Na+ channel blocker.
    QX-222 chloride
  • HY-B0836R
    λ-Cyhalothrin (Standard)
    Inhibitor
    λ-Cyhalothrin (Standard) is the analytical standard of λ-Cyhalothrin. This product is intended for research and analytical applications. λ-Cyhalothrin is a high efficiency, broad-spectrum type II synthetic pyrethroid insecticide containing α-cyano group. λ-Cyhalothrin is used to control a wide range of pests in a variety of applications. λ-Cyhalothrin is a neurotoxin that targets sodium channels in the membranes of neurons in the central nervous system.
    λ-Cyhalothrin (Standard)
  • HY-105285
    Piromelatine
    Inhibitor 99.70%
    Piromelatine (Neu-P11) is a melatonin MT1/MT2 receptor agonist, serotonin 5-HT1A/5-HT1D agonist, and serotonin 5-HT2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities.
    Piromelatine
  • HY-W357818
    Glycinexylidide
    Inhibitor
    Glycinexylidide (GX) is the active metabolite of Lidocaine. Lidocaine is a local agent that can suppress or relieve pain, that inhibits sodium channels involving complex voltage and dependence. Lidocaine also reduces the growth, migration and invasion of gastric cancer cells. Glycinexylidide has research potential for use in anesthesia, cancer, and cardiovascular disease.
    Glycinexylidide
  • HY-N9404
    6-Benzoylheteratisine
    Inhibitor 99.58%
    6-Benzoylheteratisine is an Aconitum alkaloid with potential neuroprotective activity. 6-Benzoylheteratisine can antagonize tetrodotoxin, inhibit the increase of [Na+]i, [Ca2+]i and glutamate release, and block sodium channels. 6-Benzoylheteratisine has an inhibitory effect on the neuronal activity underlying epileptiform burst discharge.
    6-Benzoylheteratisine
  • HY-B1551
    Benzonatate
    Inhibitor 98.96%
    Benzonatate (Benzononatine) is an orally active and non-narcotic peripheral antitussive agent. Benzonatate is a reversible voltage-gated Na+ channels inhibitor. Benzonatate dampens the activity of cough stretch receptors.
    Benzonatate
  • HY-178281
    E0199
    Inhibitor 99.89%
    E0199 is a novel potent dual-target KV7/NaV modulator that activates the KV7 channel (KV7.2/7.3 (EC50 = 12.78 nM), KV7.2 (EC50 = 0.50 μM), and KV7.5 (EC50 = 27.14 nM) channels) while simultaneously blocks the NaV1.7 (IC50 = 0.52 μM), NaV1.8 (IC50 = 0.24 μM), and NaV1.9 (IC50 = 0.16 μM) channels. E0199 shows a potent analgesic effect without affecting heart and skeletal muscle ion channels critically in a chronic constriction injury (CCI) mouse model. E0199 can be used for Neuropathic pain (NP) research.
    E0199
  • HY-B0448AR
    Phenytoin sodium (Standard)
    Inhibitor
    Phenytoin (sodium) (Standard) is the analytical standard of Phenytoin (sodium). This product is intended for research and analytical applications. Phenytoin sodium (5,5-Diphenylhydantoin sodium salt) is a potent Voltage-gated Na+ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice.
    Phenytoin sodium (Standard)
  • HY-156596
    Aneratrigine
    Inhibitor 99.60%
    Aneratrigine is a selective Nav1.7 inhibitor with an IC50 of 19 nM. Aneratrigine is applicable for pain-related research.
    Aneratrigine
  • HY-B0448R
    Phenytoin (Standard)
    Inhibitor
    Phenytoin (Standard) is the analytical standard of Phenytoin. This product is intended for research and analytical applications. Phenytoin (5,5-Diphenylhydantoin) is a potent Voltage-gated Na+ channels (VGSCs) blocker. Phenytoin has antiepileptic activity and reduces breast tumour growth and metastasis in mice.
    Phenytoin (Standard)
  • HY-B0122R
    Topiramate (Standard)
    Inhibitor
    Topiramate (Standard) is the analytical standard of Topiramate. This product is intended for research and analytical applications. Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
    Topiramate (Standard)
  • HY-A0078
    Mebeverine hydrochloride
    Inhibitor 99.85%
    Mebeverine hydrochloride, a β-phenylethylamine derivative, is a musculotropic agent that potently blocks intestinal peristalsis. Mebeverine directly blocks voltage-operated sodium channels and inhibits intracellular calcium accumulation.
    Mebeverine hydrochloride
  • HY-114301A
    PF-06305591 dihydrate
    Inhibitor 99.84%
    PF-06305591 dihydrate is a potent and highly selective voltage gated sodium channel NaV1.8 blocker, with an IC50 of 15 nM. An excellent preclinical in vitro ADME and safety profile.
    PF-06305591 dihydrate
  • HY-145558
    Bliretrigine
    Inhibitor 99.42%
    Bliretrigine is a sodium channel blocker. Bliretrigine has the effect of relieving pain.
    Bliretrigine
  • HY-B0480A
    Brompheniramine
    Inhibitor 99.82%
    Brompheniramine ((±)-Brompheniramine) is a potent and orally active antihistamine of the alkylamine class. Brompheniramine is a selective histamine H1 receptor antagonist with a Kd of 6.06 nM. Brompheniramine can block the hERG channels, calcium channels, and sodium channels with IC50s of 0.90 μM, 16.12 μM and 21.26 μM, respectively. Brompheniramine has anticholinergic, antidepressant and anesthetic properties and can be used for allergic rhinitis research.
    Brompheniramine
  • HY-101245
    Pilsicainide hydrochloride
    Inhibitor 99.94%
    Pilsicainide hydrochloride (SUN-1165) is an orally active sodium channel blocker and potent class Ic antiarrhythmic agent.
    Pilsicainide hydrochloride
  • HY-P1073
    ProTx-I
    Inhibitor
    ProTx-I is a toxin derived from Thrixopelma pruriens and a peptide inhibitor targeting TTX-resistant sodium channels. ProTx-I interacts with voltage sensors of multiple domains such as NaV1.7, reduces neuronal excitability through allosteric modulation of channel gating and alteration of voltage dependence. The IC50 values of ProTx-I against human NaV1.7, NaV1.2, NaV1.6, and NaV1.5 are 95 nM, 104 nM, 21 nM, and 358 nM, respectively; ProTx-I also potently inhibits Ba2+ currents of hCav3.1, while its inhibitory potency against hCav3.2 is approximately 160-fold lower. ProTx-I is applicable to the research of chronic pain.
    ProTx-I
  • HY-169294
    SLC6A8 corrector 1
    Inhibitor 99.94%
    SLC6A8 corrector 1 is an orally active and brain-penetrant mutant SLC6A8 variant corrector. SLC6A8 corrector 1 can be used for the study of creatine transporter deficiency (CTD).
    SLC6A8 corrector 1
  • HY-164795
    SBI-810
    Inhibitor 98.25%
    SBI-810 is a blood-brain barrier-permeable NTSR1 modulator. SBI-810 promotes the recruitment of β-arrestin-2 to NTSR1 and antagonizes NTSR1-mediated Gq activation. SBI-810 inhibits excitatory synaptic transmission, NMDA receptor and extracellular signal-regulated kinase (ERK) signaling in spinal nociceptive neurons, reduces surface expression of Nav1.7 and action potential firing in primary sensory neurons, and attenuates C-fiber responses. SBI-810 effectively alleviates acute and chronic pain in various rodent models through peripheral and central modulation. SBI-810 is applicable to research related to multiple pain disorders.
    SBI-810
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.